ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD)

CAPS Rating: 3 out of 5

The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Recs

0
Player Avatar HaggardFrodo (< 20) Submitted: 4/19/2007 4:46:20 PM : Outperform Start Price: $14.86 ACAD Score: -85.31

Low market cap related to potential for drug candidates. Requires patience - buy on dips

Featured Broker Partners


Advertisement